Clinical Trial Update: Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Novartis is conducting a Phase 2 platform study to evaluate investigational compounds for moderate to severe atopic dermatitis, and the trial is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Investigational compound(s) platform study

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING